Dajia Weikang: Announcement on No Profit Distribution in 2025
Securities code: 301126 Securities abbreviation: Dajia Weikang Announcement number: 2026-011
Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
Announcement on No Profit Distribution in 2025
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
The profit distribution plan of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. (hereinafter referred to as the "Company") for 2025 is as follows: no cash dividends, no bonus shares, and capital reserve funds will not be converted into share capital.
The company does not violate the relevant provisions of Article 9.4 of the "Shenzhen Stock Exchange GEM Stock Listing Rules" that may be subject to other risk warnings.
1. Review procedure
The company held the 19th meeting of the fourth board of directors on April 24, 2026, and reviewed and approved the "Proposal on No Profit Distribution in 2025." The board of directors believed that this profit distribution plan complied with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the Articles of Association and other relevant regulations. Taking into account the company's actual operating conditions, future business development and capital needs, the board of directors agreed that the company would not distribute profits in 2025. This proposal still needs to be submitted to the company's shareholders' meeting for review.
2. Basic situation of profit distribution plan
According to the standard unqualified audit report issued by Tianjian Accounting Firm (Special General Partnership) on the company's 2025 financial report, the net profit attributable to shareholders of the listed company in 2025 was -242,458,514.29 yuan, and the parent company realized a net profit of 8,540,697.16 yuan. The accumulated undistributed profit at the end of 2025 in the consolidated statement is 296,579,805.67 yuan, and the accumulated undistributed profit at the end of 2025 in the parent company's statement is 42,467,304.64 yuan. According to the provisions of the Company Law and the Articles of Association, 10% of the parent company's net profit in 2025 will be withdrawn as a statutory reserve fund of RMB 854,069.72.
Based on the company's actual operating conditions, combined with relevant provisions such as "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies" and the "Articles of Association", and comprehensively considering the company's actual operations and future development, in order to improve the company's financial stability, protect the normal operation of the company's production and operations and the long-term interests of all shareholders, the company plans not to distribute cash dividends, give out bonus shares, or convert capital reserve funds into share capital in 2025.
3. Details of cash dividend plan
- The company does not have any other risk warning situations that may trigger it
Unit: Yuan Currency: RMB
Item 2025 2024 Total cash dividends in 2023 (yuan) 4,518,870.40 16,801,981.76 8,260,228.00 Total repurchase and cancellation (yuan) Note 0 10,003,118.00 0 Net profit attributable to shareholders of listed companies (yuan) -242,458,514.29 26,574,897.24 34,299,844.15 R&D investment (yuan) 11,848,301.99 16,257,767.71 7,173,235.40 Operating income (yuan) 5,144,237,123.45 5,233,420,808.02 3,903,503,781.52 Consolidated statements Accumulated undistributed profits at the end of the year
296,579,805.67
(yuan)
Accumulated undistributed profits at the end of the year in the parent company's statement
42,467,304.64
Run (yuan)
Whether the listing has been completed for three complete fiscal years? Yes
Total cumulative cash dividends for the past three fiscal years
29,581,080.16
Amount (yuan)
The total number of repurchases and write-offs in the past three fiscal years has been
10,003,118.00
Amount (yuan)
Average net profit in the last three fiscal years (yuan) -60,527,924.30
Accumulated cash dividends in the last three fiscal years and
39,584,198.16
Total amount of repurchase and cancellation (yuan)
Total cumulative R&D investment in the past three fiscal years
35,279,305.10
Amount (yuan)
Total cumulative R&D investment in the past three fiscal years
0.2470%
Proportion of total operating income to cumulative operating income (%)
Whether it touches Article 1 of the GEM Stock Listing Rules?
The provisions of Article 9.4 (8) may be implemented No
Other risk warning situations
Note: On October 24, 2025, and November 13, 2025, the company held respectively the 17th meeting of the fourth board of directors and the third extraordinary shareholders' meeting in 2025 to review and approve the "Proposal on the Profit Distribution Plan for the First Three Quarters of 2025", and disclosed the "Announcement on the Profit Distribution Plan for the First Three Quarters of 2025" on October 28, 2025. As of On September 30, 2025, the company's total share capital was 205,403,200 shares, and a cash dividend of RMB 0.22 (tax included) was distributed to all shareholders for every 10 shares, for a total cash dividend of RMB 4,518,870.40 (tax included). No bonus shares will be given in this profit distribution, and capital reserves will not be converted into share capital. The remaining undistributed profits will be carried forward for distribution in subsequent years. Profit distribution for the first three quarters of 2025 has been completed in December 2025.
- Specific reasons for not touching other risk warning situations
The company's net profit in 2025 is negative and does not meet the conditions for cash dividends. Therefore, it does not trigger other risk warning situations that may be implemented as stipulated in Article 9.4 (8) of the GEM Stock Listing Rules.
- Reasonable explanation of cash dividend plan
The company's profit distribution plan complies with relevant regulations such as the "Company Law", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies", "Listed Companies Supervision Guidelines No. 3 - Cash Dividends for Listed Companies" and the "Articles of Association". In view of the negative net profit of the company in 2025, taking into account the company's actual operating conditions, future business development and capital needs, ensuring the sustainable and stable operation and business development of the company's production and operation, and improving the company's long-term development capabilities and profitability, no profit distribution is planned in 2025, and the capital reserve will not be converted into share capital. The company's undistributed profits will be carried forward for distribution in subsequent years to ensure that necessary and sufficient funds are provided for the company's long-term development, and to provide investors with more stable and long-term returns.
4. Related risk warnings
This matter still needs to be reviewed and approved by the company's 2025 annual shareholders' meeting before it can be implemented. Investors are kindly requested to invest rationally and pay attention to investment risks.
5. Documents for reference
- Resolution of the 19th meeting of the fourth board of directors.
Announcement is hereby made.
Board of Directors of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.
April 28, 2026